JPMorgan Chase & Co. grew its stake in ICU Medical, Inc. (NASDAQ:ICUI) by 1.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 417,744 shares of the medical instruments supplier’s stock after acquiring an additional 5,356 shares during the period. JPMorgan Chase & Co. owned 2.11% of ICU Medical worth $72,061,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Creative Planning raised its stake in shares of ICU Medical by 315.6% in the first quarter. Creative Planning now owns 665 shares of the medical instruments supplier’s stock worth $102,000 after acquiring an additional 505 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of ICU Medical by 10.3% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 707 shares of the medical instruments supplier’s stock worth $122,000 after acquiring an additional 66 shares during the last quarter. Victory Capital Management Inc. raised its stake in shares of ICU Medical by 17.6% in the second quarter. Victory Capital Management Inc. now owns 1,050 shares of the medical instruments supplier’s stock worth $181,000 after acquiring an additional 157 shares during the last quarter. Parametrica Management Ltd bought a new position in shares of ICU Medical in the second quarter worth about $213,000. Finally, Teacher Retirement System of Texas bought a new position in shares of ICU Medical in the second quarter worth about $214,000. 78.13% of the stock is owned by institutional investors.
Shares of ICU Medical, Inc. (NASDAQ ICUI) opened at 177.35 on Monday. The stock’s 50 day moving average is $171.40 and its 200 day moving average is $162.77. ICU Medical, Inc. has a 12 month low of $120.14 and a 12 month high of $178.20. The firm has a market cap of $3.52 billion, a PE ratio of 71.03 and a beta of 0.36.
ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings data on Wednesday, August 9th. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.58 by $0.06. The business had revenue of $331.51 million during the quarter, compared to the consensus estimate of $318.30 million. ICU Medical had a net margin of 6.10% and a return on equity of 7.56%. The firm’s quarterly revenue was up 242.8% compared to the same quarter last year. During the same quarter last year, the business earned $1.15 EPS. Analysts forecast that ICU Medical, Inc. will post $4.11 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “ICU Medical, Inc. (ICUI) Shares Bought by JPMorgan Chase & Co.” was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://sportsperspectives.com/2017/09/11/icu-medical-inc-icui-shares-bought-by-jpmorgan-chase-co.html.
A number of equities analysts have weighed in on ICUI shares. BidaskClub raised shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Saturday, June 17th. Zacks Investment Research raised shares of ICU Medical from a “hold” rating to a “buy” rating and set a $193.00 target price for the company in a research note on Thursday, July 20th. Gabelli reaffirmed a “buy” rating on shares of ICU Medical in a research note on Friday, August 11th. Finally, Sidoti cut shares of ICU Medical from a “buy” rating to a “neutral” rating in a research report on Tuesday, June 20th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the company’s stock. ICU Medical currently has an average rating of “Hold” and an average target price of $193.00.
In related news, CEO Vivek Jain sold 69,014 shares of the firm’s stock in a transaction that occurred on Friday, July 7th. The shares were sold at an average price of $171.10, for a total value of $11,808,295.40. Following the completion of the transaction, the chief executive officer now owns 110,925 shares in the company, valued at approximately $18,979,267.50. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Virginia Ruth Sanzone sold 1,784 shares of the firm’s stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $174.47, for a total transaction of $311,254.48. Following the completion of the transaction, the vice president now owns 102 shares of the company’s stock, valued at approximately $17,795.94. The disclosure for this sale can be found here. In the last quarter, insiders sold 212,549 shares of company stock valued at $36,354,740. 15.90% of the stock is owned by company insiders.
ICU Medical Company Profile
ICU Medical, Inc is engaged in the development, manufacture and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.
Receive News & Ratings for ICU Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.